Business
Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that members of its team will join the Prader-Willi syndrome (PWS) community at the 2025 United in Hope Conference, taking place June 24 to 28 in Phoenix, Arizona. “It’s an honor to stand alongside the f
About this update from Aardvark Therapeutics, Inc.
[{"type":"image","alt":"Aardvark Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Aardvark Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":63,"url":"https://media.zenfs.com/en/globenewswire.com/fe55bd926bdb60296161677c87a21101"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_2n1g9xWdfu1GQlbvtkO7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/fe55bd926bdb60296161677c87a21101","width":300,"height":63}},"lazy":false},{"type":"text","content":"SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that members of its team will join the Prader-Willi syndrome (PWS) community at the 2025 United in Hope Conference, taking place June 24 to 28 in Phoenix, Arizona.","length":460,"tagName":"p"},{"type":"text","content":"“It’s an honor to stand alongside the families, advocates, scientists and clinicians who are working to transform the lives of those affected by PWS,” said Dr. Tien Lee, Chief Executive Officer of Aardvark Therapeutics. “The United in Hope Conference is a powerful reflection of the passion, resilience and shared purpose that drive our mission. We’re proud to contribute to the clinical dialogue and deeply value the opportunity to strengthen our partnership with this extraordinary community.”","length":495,"tagName":"p"},{"type":"text","content":"During the clinical and scientific program, Aardvark will present previously disclosed data from its Phase 2 study of ARD-101 in PWS in both a poster and a five-minute “lightning” oral presentation, both entitled “Reduction in Hyperphagia in the ARD-101 Phase 2 Clinical Trial Informs Phase 3 HERO Trial in PWS.” The presentations will highlight ARD-101’s favorable safety profile in PWS as well as early evidence for reduced hyperphagia, all of which informed the design of the ongoing Phase 3 HERO study, which is currently enrolling patients with PWS.","length":554,"tagName":"p"},{"type":"text","content":"Within the family program agenda, Aardvark’s Chief Medical Officer, Manasi Jaiman, M.D., will join a panel of clinicians to discuss the details of th...